Report Detail

Request for Sample of this report

Medical Devices & Consumables Global KRAS Inhibitor Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

  • RnM4659421
    • |
  • 31 December, 2025
    • |
  • Global
    • |
  • 105 Pages
    • |
  • GIR
    • |
  • Medical Devices & Consumables

According to our (Global Info Research) latest study, the global KRAS Inhibitor market size was valued at US$ 138 million in 2024 and is forecast to a readjusted size of USD 237 million by 2031 with a CAGR of 8.1% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
This report is a detailed and comprehensive analysis for global KRAS Inhibitor market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global KRAS Inhibitor market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global KRAS Inhibitor market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for KRAS Inhibitor
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global KRAS Inhibitor market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
KRAS Inhibitor market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Lung Cancer
Pancreatic Cancer
Colorectal Cancer
Others
Market segment by Application
Clinic Laboratories
Cancer Diagnostic Centres
Hospitals
Others
Major players covered
Amgen
Boehringer Ingelheim
BridgeBio Pharma
Erasca
Innovent Biologics
Incyte
Mirati Therapeutics
Novartis
Jemincare
Cardiff Oncology
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe KRAS Inhibitor product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of KRAS Inhibitor, with price, sales quantity, revenue, and global market share of KRAS Inhibitor from 2020 to 2025.
Chapter 3, the KRAS Inhibitor competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the KRAS Inhibitor breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and KRAS Inhibitor market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of KRAS Inhibitor.
Chapter 14 and 15, to describe KRAS Inhibitor sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global KRAS Inhibitor Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Lung Cancer
    • 1.3.3 Pancreatic Cancer
    • 1.3.4 Colorectal Cancer
    • 1.3.5 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global KRAS Inhibitor Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Clinic Laboratories
    • 1.4.3 Cancer Diagnostic Centres
    • 1.4.4 Hospitals
    • 1.4.5 Others
  • 1.5 Global KRAS Inhibitor Market Size & Forecast
    • 1.5.1 Global KRAS Inhibitor Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global KRAS Inhibitor Sales Quantity (2020-2031)
    • 1.5.3 Global KRAS Inhibitor Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 Amgen
    • 2.1.1 Amgen Details
    • 2.1.2 Amgen Major Business
    • 2.1.3 Amgen KRAS Inhibitor Product and Services
    • 2.1.4 Amgen KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Amgen Recent Developments/Updates
  • 2.2 Boehringer Ingelheim
    • 2.2.1 Boehringer Ingelheim Details
    • 2.2.2 Boehringer Ingelheim Major Business
    • 2.2.3 Boehringer Ingelheim KRAS Inhibitor Product and Services
    • 2.2.4 Boehringer Ingelheim KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.3 BridgeBio Pharma
    • 2.3.1 BridgeBio Pharma Details
    • 2.3.2 BridgeBio Pharma Major Business
    • 2.3.3 BridgeBio Pharma KRAS Inhibitor Product and Services
    • 2.3.4 BridgeBio Pharma KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 BridgeBio Pharma Recent Developments/Updates
  • 2.4 Erasca
    • 2.4.1 Erasca Details
    • 2.4.2 Erasca Major Business
    • 2.4.3 Erasca KRAS Inhibitor Product and Services
    • 2.4.4 Erasca KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Erasca Recent Developments/Updates
  • 2.5 Innovent Biologics
    • 2.5.1 Innovent Biologics Details
    • 2.5.2 Innovent Biologics Major Business
    • 2.5.3 Innovent Biologics KRAS Inhibitor Product and Services
    • 2.5.4 Innovent Biologics KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Innovent Biologics Recent Developments/Updates
  • 2.6 Incyte
    • 2.6.1 Incyte Details
    • 2.6.2 Incyte Major Business
    • 2.6.3 Incyte KRAS Inhibitor Product and Services
    • 2.6.4 Incyte KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Incyte Recent Developments/Updates
  • 2.7 Mirati Therapeutics
    • 2.7.1 Mirati Therapeutics Details
    • 2.7.2 Mirati Therapeutics Major Business
    • 2.7.3 Mirati Therapeutics KRAS Inhibitor Product and Services
    • 2.7.4 Mirati Therapeutics KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Mirati Therapeutics Recent Developments/Updates
  • 2.8 Novartis
    • 2.8.1 Novartis Details
    • 2.8.2 Novartis Major Business
    • 2.8.3 Novartis KRAS Inhibitor Product and Services
    • 2.8.4 Novartis KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Novartis Recent Developments/Updates
  • 2.9 Jemincare
    • 2.9.1 Jemincare Details
    • 2.9.2 Jemincare Major Business
    • 2.9.3 Jemincare KRAS Inhibitor Product and Services
    • 2.9.4 Jemincare KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 Jemincare Recent Developments/Updates
  • 2.10 Cardiff Oncology
    • 2.10.1 Cardiff Oncology Details
    • 2.10.2 Cardiff Oncology Major Business
    • 2.10.3 Cardiff Oncology KRAS Inhibitor Product and Services
    • 2.10.4 Cardiff Oncology KRAS Inhibitor Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Cardiff Oncology Recent Developments/Updates

3 Competitive Environment: KRAS Inhibitor by Manufacturer

  • 3.1 Global KRAS Inhibitor Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global KRAS Inhibitor Revenue by Manufacturer (2020-2025)
  • 3.3 Global KRAS Inhibitor Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of KRAS Inhibitor by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 KRAS Inhibitor Manufacturer Market Share in 2024
    • 3.4.3 Top 6 KRAS Inhibitor Manufacturer Market Share in 2024
  • 3.5 KRAS Inhibitor Market: Overall Company Footprint Analysis
    • 3.5.1 KRAS Inhibitor Market: Region Footprint
    • 3.5.2 KRAS Inhibitor Market: Company Product Type Footprint
    • 3.5.3 KRAS Inhibitor Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global KRAS Inhibitor Market Size by Region
    • 4.1.1 Global KRAS Inhibitor Sales Quantity by Region (2020-2031)
    • 4.1.2 Global KRAS Inhibitor Consumption Value by Region (2020-2031)
    • 4.1.3 Global KRAS Inhibitor Average Price by Region (2020-2031)
  • 4.2 North America KRAS Inhibitor Consumption Value (2020-2031)
  • 4.3 Europe KRAS Inhibitor Consumption Value (2020-2031)
  • 4.4 Asia-Pacific KRAS Inhibitor Consumption Value (2020-2031)
  • 4.5 South America KRAS Inhibitor Consumption Value (2020-2031)
  • 4.6 Middle East & Africa KRAS Inhibitor Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global KRAS Inhibitor Sales Quantity by Type (2020-2031)
  • 5.2 Global KRAS Inhibitor Consumption Value by Type (2020-2031)
  • 5.3 Global KRAS Inhibitor Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global KRAS Inhibitor Sales Quantity by Application (2020-2031)
  • 6.2 Global KRAS Inhibitor Consumption Value by Application (2020-2031)
  • 6.3 Global KRAS Inhibitor Average Price by Application (2020-2031)

7 North America

  • 7.1 North America KRAS Inhibitor Sales Quantity by Type (2020-2031)
  • 7.2 North America KRAS Inhibitor Sales Quantity by Application (2020-2031)
  • 7.3 North America KRAS Inhibitor Market Size by Country
    • 7.3.1 North America KRAS Inhibitor Sales Quantity by Country (2020-2031)
    • 7.3.2 North America KRAS Inhibitor Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe KRAS Inhibitor Sales Quantity by Type (2020-2031)
  • 8.2 Europe KRAS Inhibitor Sales Quantity by Application (2020-2031)
  • 8.3 Europe KRAS Inhibitor Market Size by Country
    • 8.3.1 Europe KRAS Inhibitor Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe KRAS Inhibitor Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific KRAS Inhibitor Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific KRAS Inhibitor Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific KRAS Inhibitor Market Size by Region
    • 9.3.1 Asia-Pacific KRAS Inhibitor Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific KRAS Inhibitor Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America KRAS Inhibitor Sales Quantity by Type (2020-2031)
  • 10.2 South America KRAS Inhibitor Sales Quantity by Application (2020-2031)
  • 10.3 South America KRAS Inhibitor Market Size by Country
    • 10.3.1 South America KRAS Inhibitor Sales Quantity by Country (2020-2031)
    • 10.3.2 South America KRAS Inhibitor Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa KRAS Inhibitor Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa KRAS Inhibitor Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa KRAS Inhibitor Market Size by Country
    • 11.3.1 Middle East & Africa KRAS Inhibitor Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa KRAS Inhibitor Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 KRAS Inhibitor Market Drivers
  • 12.2 KRAS Inhibitor Market Restraints
  • 12.3 KRAS Inhibitor Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of KRAS Inhibitor and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of KRAS Inhibitor
  • 13.3 KRAS Inhibitor Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 KRAS Inhibitor Typical Distributors
  • 14.3 KRAS Inhibitor Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on KRAS Inhibitor. Industry analysis & Market Report on KRAS Inhibitor is a syndicated market report, published as Global KRAS Inhibitor Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031. It is complete Research Study and Industry Analysis of KRAS Inhibitor market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo